Some observations on the pathogenesis of Bartter's syndrome.
D000328:Adult; D000450:Aldosterone / Q000378:metabolism; D000471:Alkalosis / Q000503:physiopathology; D000804:Angiotensin II / Q000494:pharmacology / Q000627:therapeutic use; D001810:Blood Volume; D004359:Drug Therapy, Combination; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology* / Q000652:urine; D006965:Hyperplasia; D006984:Hypertrophy; D007008:Hypokalemia / Q000503:physiopathology; D007606:Juxtaglomerular Apparatus; D007668:Kidney / Q000503:physiopathology; D007674:Kidney Diseases / Q000503:physiopathology*; D008297:Male; D011188:Potassium / Q000097:blood; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000494:pharmacology / Q000627:therapeutic use
D000804:Angiotensin II; D013148:Spironolactone; D000450:Aldosterone; D011433:Propranolol; D012083:Renin; D011188:Potassium